Rezafungin acetate is under clinical development by Napp Pharmaceuticals and currently in Phase III for Aspergillosis.

This data was used to create simulations that show how the fungal cell walls change in response to these drugs. After echinocandin exposure, fungi alter the organization of the parts in their cell ...

The team found that when exposed to echinocandin, the fungi enhance their survival odds by making specific changes to the structure and organization of the components in their cell walls.

The pharmacology, bioavailability and pharmacokinetics, clinical efficacy, and adverse effects of caspofungin acetate are reviewed. Caspofungin acetate is an echinocandin with fungicidal activity ...

Amphotericin B deoxycholate 0.6–1 mg/kg +/− flucytosine 25 mg/kg four times daily Echinocandin** *Anidulafungin 200 mg loading dose, then 100 mg/day; Caspofungin 70 mg loading dose ...